Skip to main content

Table 4 Cost of TKI therapy and cost of related unwanted effects (UE). Amounts are presented in MXN pesos

From: Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

  Afatinib
(n = 40)
Erlotinib
(n = 26)
Gefitinib
(n = 33)
p-value
Mean (SD) Median Mean (SD) Median Mean (SD) Median
TKI cost
Daily cost 722 (130) 765 794 (96) 819 451 (0) 451 <  0.001
Total cost 337,325 (299,832) 238,298 200,506 (137,831) 183,384 149,645 (107,139) 126,299 <  0.001
UE cost
Medications 6846 (21,203) 2485 3479 (5727) 897 2212 (4762) 98 <  0.05
Consultation 4373 (5751) 1732 3797 (4382) 2598 4304 (6125) 1732 0.843
Total 11,219 (23,734) 6948 7276 (8498) 5267 6516 (8986) 2719 0.262
TOTAL
TKI + UE
348,544 (311,386) 246,258 207,782 (143,566) 186,685 156,161 (111,330) 126,299 <  0.001